Redeye comments on Fluoguide raising cSEK60m through a directed share issue.
Redeye comments on Curasight announced financing solution.
Med pusselbitarna på plats accelererade lyftet för kursen i februari, men potential finns kvar i akt...
Q2 report due 18 July We forecast SEK 561m net sales, SEK 81m EBITA Fair value range raised to SEK 4...
Q2e: sales +18% and EBITDA +38% y-o-y We raise our EBITDA estimates by 10-6% on '24e-'26e Positive E...
2024 likely to be back-end loaded Company still expects 3-5 more design wins in 2024 Guidance implie...
Under Q1-24 har Syncro Group (”Koncernen”) fortsatt att exekvera på tillväxtstrategin som lanserades...
Redeye leaves a comment following Lipum’s announcement of further clinical advancements in the ongoi...
VNV Global är investmentbolaget som ger en unik möjlighet till att få exponering mot onoterade snabb...
Vultus AB (publ) (”Vultus” eller ”Bolaget”) erbjuder marknadsledande tjänster, vilket inkluderar fjä...
Redeye updates its estimates for the Q2 2024 report (due 2024-07-18).
Q2e: 0% organic growth and stable margins Higher central costs behind 3-2% cuts to adj.
Circio presents a scientific update on the pre-clinical work with the circular RNA platform.
STENOCARE announced on June 17th that the company is planning an expansion into Canada together with...
The announcement of the updated DFS for Dannemora showed, as expected, higher CAPEX and OPEX compare...
Under H1-24 har Luxbright AB (”Luxbright” eller ”Bolaget”) erhållit ordrar om ca 15 MSEK, och det ko...
Redeye comments on GiG’s acquisition of the SEO and content service supplier Titan Inc, which is exp...
Redeye comments on Lifecare after the announcement that its rights issue was oversubscribed, reinfor...
Redeye initiates coverage of Coegin Pharma, a hub and spoke biotech company with a diverse array of ...
Redeye expects a solid Q2 report from Proact, although we want to highlight that investors should no...
